

A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars

NCT07207369

Status	RECRUITING
Phase	Phase 3
Sponsor	AbbVie
Enrollment	395 participants

Key Eligibility Criteria

Inclusion (3)

- Participants in general good health, and seeking improvement of atrophic acne scars.
- Moderate to severe atrophic acne scarring (Grade 4 or 5 on the Allergan Acne Scar Improvement Scale \[ASIS\]) on each cheek based on evaluating investigator (EI) live assessment (both cheeks must qualify but do not need to have the same score) at the first Screening Visit.
- At least 5 rolling or boxcar-type acne scars in total within the predefined 4 cm x 4 cm assessment field of either cheek in areas of otherwise normal healthy skin, as assessed by the treating investigator (TI).

Exclusion (4)

- The participant has clinically significant acne on the face.
- Current cutaneous or mucosal inflammatory or infectious processes other than acne (eg, herpes), rosacea, abscess, an unhealed wound, or a cancerous or precancerous lesion, on the face.
- The participant presents with predominantly ice pick scars.
- History of keloid scar formation, hypertrophic scarring, and/or post inflammatory hyperpigmentation or hypopigmentation.

Locations (10 total)

Advanced Research Associates - Glendale /ID# 254961, Glendale, Arizona, United States
Marcus Facial Plastic Surgery /ID# 275880, Redondo Beach, California, United States
Pacific Clinical Innovations /ID# 256185, Vista, California, United States
... and 7 more locations